Table of Contents
Introduction
Global Women’s Health Market size is expected to be worth around US$ 66 Billion by 2033, from US$ 41.3 Billion in 2023, growing at a CAGR of 4.8% during the forecast period from 2024 to 2033. In 2023, North America led the market, achieving over 38.7% share with a revenue of US$ 15.9 Billion.
This growth is fueled by advancements in medical technologies such as telehealth and personalized medicine, which improve accessibility and provide customized treatments, especially in mental health and preventive care.
The market faces challenges including stringent regulatory environments and high treatment costs. Regulatory barriers, such as restrictive abortion laws in several regions, significantly influence market dynamics by affecting product availability and service delivery. Moreover, the high cost of healthcare limits access to essential treatments, particularly in underdeveloped regions. According to the World Bank, over 100 million people are pushed into poverty annually due to healthcare costs, with women disproportionately affected.
Despite these obstacles, the market is expanding due to increased awareness of women’s health needs and technological advancements. Efforts to overcome challenges include innovations in diagnostics and treatments and enhanced government initiatives aimed at improving healthcare access and quality for women. For instance, growing investments in women-focused health technologies highlight a shift toward more tailored healthcare solutions.
The sector is experiencing robust growth and transformation, bolstered by significant investments in areas like fertility treatments and telemedicine. In May 2023, MegaFood launched a new supplement line targeting women’s hormonal and mood balance, reflecting the market’s adaptability to women-specific health requirements.
Additionally, rising investments in women’s health demonstrate a broader recognition of its societal and economic importance. In 2023, funding in health technology for women surged, signifying a commitment to inclusive healthcare innovation. The U.S. government also announced a $100 million investment in women’s health research to address historical funding gaps.
Overall, the women’s health market is positioned for sustained growth, supported by advanced treatments, increasing awareness, and robust investments. This combination sets a strong foundation for further developments in this essential sector.
Key Takeaways
- The Women’s Health Market is estimated to increase from USD 41.3 billion in 2023 to USD 66 billion by 2033, achieving a 4.8% CAGR.
- Dominating the market segments, gynecological conditions account for over 37% due to increased disease prevalence and diagnostic and treatment improvements.
- Adult women are the predominant age group in the market, representing more than 46%, which underscores the varied healthcare requirements from reproduction to chronic disease management.
- North America holds a leading position in the global market with a 38.7% share, amounting to USD 15.9 billion in 2023, propelled by robust healthcare infrastructure and heightened awareness.
Women’s Health Statistics (2022)
- High Blood Pressure Testing
- 36% of women were tested for high blood pressure, up from 33% in 2020.
- Nearly 2 billion women were unscreened, including over 500 million women aged 40 and older.
- Cancer Testing
- 11% of women were tested for any type of cancer, unchanged from previous years.
- Among women aged 40-49, testing rates dropped to 11%, down from 17% in 2020.
- Diabetes Testing
- 19% of women were tested for diabetes, consistent with previous years.
- 81% of women have not been tested for diabetes in the last three years.
- STD/STI Testing
- Only 10% of women were tested for STDs/STIs, consistent with previous years.
- Nearly 2 billion women of reproductive age were unscreened for STDs/STIs.
- Emotional Well-being
- 4 in 10 women experienced worry and stress during the previous day.
- 3 in 10 women felt sadness, and 1 in 4 experienced anger.
- Women are 20% more likely than men to feel sadness daily.
- Safety Concerns
- 34% of women do not feel safe walking alone at night in their communities.
- Over 40% of women aged 15-24 feel unsafe walking alone at night.
- Satisfaction with Healthcare
- Nearly 70% of women are satisfied with the availability of quality healthcare.
- Satisfaction levels have increased compared to previous years.
- Affordability of Basic Needs
- Nearly 1 billion women worldwide struggle to afford food or shelter.
- 3 in 10 women cannot afford basic necessities like food and shelter.
- Physical Health
- 1 in 3 women experienced physical pain during much of the previous day.
- 1 in 4 women have health issues preventing normal daily activities.
- Physical Activity
- In 2020, only 20.4% of women met aerobic and muscle-strengthening guidelines.
- Physical activity decreases with age: 28.7% (18-34 years) meet guidelines, compared to 10.8% (65+ years).
- Non-Hispanic White women (24.3%) are more active than Hispanic (18.0%) and non-Hispanic Black women (16.5%).
- Women with family income above 200% of the federal poverty level (25.9%) are more active than those below the poverty line (9.9%).
- Health and Economic Impacts
- Women live longer but spend 25% more years in poor health.
- Closing the women’s health gap could add 7 quality life days annually for 3.9 billion women worldwide.
- Addressing the gap could increase global GDP by $1 trillion by 2040, equivalent to 137 million full-time jobs.
- 64 conditions account for 86% of the global female disease burden (excluding injuries).
- Only 5% of the women’s health burden comes from sexual and reproductive health, while nearly 50% is from conditions like headaches and autoimmune diseases.
- Diagnosis and Treatment Gaps
- Women experience 15-40% more years in poor health than men globally.
- In the US, women spend 18% more years in poor health than men.
- In lowand middle-income countries, poor maternal health and high childbirth mortality rates exacerbate the health gap.
- Differences in care delivery account for 1/3 of the women’s health gap.
- Fewer than 50% of US women with endometriosis have a documented diagnosis.
- Women are diagnosed later than men for certain cancers and diabetes.
- Only 50% of 650 research papers analyzed sex-disaggregated data, with 2/3 showing disadvantages for women.
- Innovations and Insights
- UNICEF’s low-cost uterine balloon tamponade device treats postpartum hemorrhage with 95% success.
- Postpartum hemorrhage kills 130,000 women globally each year.
- Only 1% of healthcare research funding focuses on female-specific conditions beyond oncology.
- Women with heart attacks are 50% more likely to be misdiagnosed than men.
- Endometriosis affects 10% of women of reproductive age globally, but only 20% of cases are diagnosed in the US.
- Girls are 3 times less likely to be diagnosed with autism compared to boys.
Emerging Trends in Women’s Health
- Personalized Health Solutions: The women’s health sector is embracing personalized healthcare, leveraging technological advancements. Health products and services increasingly use biometric data to offer tailored recommendations. Generative AI integration into apps and wearables enables the creation of individualized wellness plans based on unique fitness metrics, enhancing the delivery of customized care.
- Rise of Female-Centric Health Brands: New brands are emerging that specifically cater to women’s health issues such as menopause, fertility, and overall wellness. These brands fill gaps often overlooked by traditional healthcare providers, offering specialized products and services tailored to women’s unique needs, fostering inclusivity in healthcare.
- Shift Towards Natural Remedies: A growing preference for natural treatments is evident as more women turn to vitamins, herbal remedies, and supplements for overall well-being. Since 2020, the use of herbal and natural medicines among American women has increased by 18%, reflecting a shift away from conventional pharmaceuticals.
- Focus on Gut Health: The link between gut health and women-specific issues like PCOS is gaining recognition. Probiotics and digestive health supplements are becoming part of daily routines as women aim to improve their overall health by prioritizing gut health.
- Innovations in Pregnancy Monitoring: Technological advancements are revolutionizing pregnancy care through digital tools and applications that sync with wearable devices. These innovations enable real-time monitoring of vital signs, providing greater autonomy and enhanced healthcare access for pregnant women.
- Growing Investments in Women’s Health: Despite a broader decline in venture capital funding, investment in women’s health technologies continues to rise, with a 5% increase recorded recently. This trend highlights the sector’s importance and potential, driving innovation and fostering advancements in women’s healthcare solutions.
Key Players in the Women’s Health Market
- AbbVie Inc.: Following its acquisition of Allergan, AbbVie inherited a strong women’s health portfolio, which it has recently sought to divest, valued at around $5 billion. This move reflects AbbVie’s strategy to reduce debts incurred during the Allergan purchase and focus on core areas like immunology and oncology, signaling a shift away from women’s health drugs.
- Bayer AG: Bayer is at the forefront of women’s health innovation, developing elinzanetant, a non-hormonal treatment for menopausal symptoms. Through its OASIS clinical program, Bayer’s Phase III results demonstrated significant improvements in managing vasomotor symptoms and enhancing sleep quality, reaffirming its commitment to addressing unmet women’s health needs.
- Merck & Co., Inc.: Merck recently spun off its women’s health division into a new independent company, Organon, allowing a focused approach to this market segment. With around 60 treatments in its portfolio, Organon aims to address global women’s healthcare needs while Merck refines its focus on core growth areas, ensuring operational efficiency and revenue growth.
- Pfizer Inc.: Pfizer’s collaboration with Myovant Sciences led to the development of MYFEMBREE, approved for treating pain from endometriosis and heavy menstrual bleeding due to uterine fibroids. This milestone highlights Pfizer’s dedication to addressing prevalent conditions and unmet needs within women’s health.
- Teva Pharmaceutical Industries Ltd.: In 2018, Teva sold its women’s health portfolio to CVC Capital Partners for $703 million, including products for contraception, fertility, menopause, and osteoporosis. This divestment was part of a broader strategy to streamline operations, reduce debt, and concentrate on core business areas.
- Agile Therapeutics: Agile has expanded the reach of its contraceptive patch, Twirla, through FPA Women’s Health. This initiative is expected to boost revenues to $25-$30 million, leveraging FPA’s extensive California network. Agile’s improved financial performance underscores its growing influence in women’s healthcare.
- Amgen Inc.: Amgen supports women’s health through campaigns like “Her Health First,” addressing osteoporosis, heart disease, and cancer. Global partnerships focus on reducing osteoporosis-related fractures, promoting both immediate care and long-term prevention strategies to enhance women’s health outcomes.
- Apothecus Pharmaceutical Corp.: Apothecus specializes in non-hormonal contraceptives, offering products like VCF Vaginal Contraceptive Film and Gel. These hormone-free solutions provide safe, effective options, widely available across U.S. retailers, reflecting their dedication to advancing women’s reproductive health.
- Blairex Laboratories Inc.: Blairex has significantly expanded its offerings in the women’s health market, focusing on over-the-counter solutions. This strategic growth positions Blairex as a key player in advancing innovative women’s health products and meeting market demands.
- Ferring B.V.: Ferring emphasizes reproductive and maternal health, actively participating in global forums like the Women’s Health Innovation Summit. These efforts highlight Ferring’s leadership in fostering partnerships and driving solutions to enhance women’s health outcomes worldwide.
Conclusion
The women’s health market is projected to grow from USD 41.3 billion in 2023 to USD 66 billion by 2033, with a CAGR of 4.8%. This growth is driven by advancements in medical technologies, such as telehealth and personalized medicine, which enhance treatment accessibility and customization. However, challenges like high treatment costs and regulatory barriers, such as restrictive abortion laws, affect market dynamics.
Key trends include rising investments in women-specific health technologies, innovations in fertility treatments, and a shift toward natural remedies. Despite these challenges, efforts to address gaps in care and improve healthcare access are fostering market expansion. Leading companies, such as Bayer and Merck, are driving innovation in women’s health, positioning the sector for sustained growth.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
